ABOS net incomeQ3 2026-$25.37M
ABOS net income was -$25.37M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$26.45M a year earlier. For the full fiscal 2025 it was -$121.33M, compared with -$102.33M in fiscal 2024.
Acumen Pharmaceuticals Inc. (ABOS) financials
For the twelve months ended Sep 30, 2026, Acumen Pharmaceuticals Inc. reported -$103.96M of net income.
- Net income, TTM
- -$103.96M
- Free cash flow, TTM
- -$87.95M
- EPS, diluted, TTM
- -$1.53
- Cash
- $53.08M
- Total debt
- $26.27M
- Market cap
- $17.6M
FY2022FY2023
FY2020FY2025
FY2021FY2025
ABOS revenue and earnings growth
ABOS EPSQ3 2026-$0.35
ABOS diluted EPS was -$0.35 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.44 a year earlier. For the full fiscal 2025 it was -$2.00, compared with -$1.71 in fiscal 2024.
ABOS free cash flowQ3 2026-$26.65M
ABOS free cash flow was -$26.65M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$30.49M a year earlier. For the full fiscal 2025 it was -$115.63M, compared with -$86.23M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $10.79M | $2.39M | - | - |
| Research and development | $104.89M | $93.80M | $42.32M | $32.36M | $12.30M | $8.00M |
| Selling, general and admin | $18.95M | $20.22M | $18.82M | $12.88M | $7.28M | $1.35M |
| Operating income | -$123.83M | -$114.02M | -$61.14M | -$45.24M | -$19.58M | -$7.91M |
| Interest expense | $4.22M | $4.07M | $581.0K | $0 | - | - |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$121.33M | -$102.33M | -$52.37M | -$42.86M | -$100.61M | -$7.33M |
| EPS, basic | -$2.00 | -$1.71 | -$1.08 | -$1.06 | -$5.02 | -$17.48 |
| EPS, diluted | -$2.00 | -$1.71 | -$1.08 | -$1.06 | -$5.02 | -$17.48 |
| Diluted shares | 60.6M | 60.0M | 48.6M | 40.6M | 20.1M | 419,124 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $53.99M | $35.86M | $67.12M | $130.10M | $122.16M | $43.78M |
| Short-term investments | $62.88M | $135.93M | $176.64M | $47.50M | $72.08M | - |
| Current assets | $122.25M | $178.31M | $246.62M | $180.33M | $198.66M | $44.43M |
| Total assets | $122.83M | $238.99M | $310.13M | $196.59M | $230.33M | $44.43M |
| Current liabilities | $30.01M | $27.61M | $12.97M | $7.81M | $5.15M | - |
| Short-term debt | $8.77M | $0 | - | - | - | - |
| Total debt | $31.16M | $29.42M | $29.90M | $0 | - | - |
| Total liabilities | $52.40M | $57.18M | $43.15M | $7.81M | $5.15M | $6.37M |
| Shareholders' equity | $70.43M | $181.82M | $266.97M | $188.78M | $225.18M | -$18.59M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$115.54M | -$86.22M | -$43.06M | -$35.15M | -$17.96M | -$7.45M |
| Capital expenditures | $88.0K | $16.0K | $21.0K | $161.0K | $40.0K | - |
| Free cash flow | -$115.63M | -$86.23M | -$43.09M | -$35.31M | -$18.00M | - |
| Investing cash flow | $133.93M | $48.03M | -$171.67M | $39.19M | -$104.12M | - |
| Financing cash flow | -$34.0K | $6.93M | $151.75M | $3.91M | $200.47M | $44.67M |
| Stock-based compensation | $9.85M | $9.63M | $6.14M | $3.06M | $922.0K | $154.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | 351.1% | - | - | - |
| Operating margin | - | - | -566.6% | -1891.2% | - | - |
| Net margin | - | - | -485.3% | -1791.6% | - | - |
| Free cash flow margin | - | - | -399.3% | -1476.3% | - | - |
| Return on equity | -172.3% | -56.3% | -19.6% | -22.7% | -44.7% | - |
| Return on assets | -98.8% | -42.8% | -16.9% | -21.8% | -43.7% | -16.5% |
| Current ratio | 4.07 | 6.46 | 19.01 | 23.08 | 38.60 | - |
| Debt to equity | 0.44 | 0.16 | 0.11 | 0.00 | - | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $4.00M | - |
| Research and development | $21.11M | $27.81M | $16.48M | $20.53M | $21.97M | $37.13M | $25.27M | $34.57M | $27.25M | $19.53M | $12.45M | $13.29M |
| Selling, general and admin | $4.70M | $4.75M | $4.67M | $4.67M | $4.54M | $4.63M | $5.10M | $5.03M | $5.02M | $4.85M | $5.33M | $5.19M |
| Operating income | -$25.81M | -$32.56M | -$21.15M | -$25.20M | -$26.51M | -$41.75M | -$30.37M | -$39.60M | -$32.27M | -$24.38M | -$17.77M | -$18.49M |
| Interest expense | $999.0K | $1.09M | $1.07M | $1.09M | $1.07M | $1.05M | $1.02M | $1.04M | $1.03M | $1.00M | $1.00M | $581.0K |
| Net income | -$25.37M | -$32.72M | -$20.74M | -$25.14M | -$26.45M | -$40.95M | -$28.80M | -$37.15M | -$29.77M | -$20.54M | -$14.87M | -$16.50M |
| EPS, basic | -$0.35 | -$0.45 | -$0.33 | -$0.40 | -$0.44 | -$0.68 | -$0.48 | -$0.62 | -$0.50 | -$0.34 | -$0.25 | - |
| EPS, diluted | -$0.35 | -$0.45 | -$0.33 | -$0.40 | -$0.44 | -$0.68 | -$0.48 | -$0.62 | -$0.50 | -$0.34 | -$0.25 | - |
| Diluted shares | 72.3M | 72.3M | 63.2M | - | 60.6M | 60.6M | 60.5M | - | 60.1M | 60.1M | 59.8M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $53.08M | $59.44M | $51.80M | $53.99M | $47.06M | $37.04M | $30.39M | $35.86M | $33.42M | $68.19M | $47.16M | $67.12M |
| Short-term investments | $25.53M | $50.75M | $76.60M | $62.88M | $79.78M | $106.56M | $118.99M | $135.93M | $167.16M | $192.52M | $205.58M | $176.64M |
| Current assets | $85.13M | $115.51M | $133.09M | $122.25M | $132.15M | $148.40M | $154.95M | $178.31M | $207.63M | $266.92M | $255.83M | $246.62M |
| Total assets | $85.56M | $116.01M | $133.63M | $122.83M | $142.22M | $171.90M | $204.48M | $238.99M | $266.98M | $288.91M | $300.97M | $310.13M |
| Current liabilities | $45.09M | $46.85M | $29.23M | $30.01M | $21.96M | $24.86M | $19.32M | $27.61M | $19.91M | $15.37M | $8.47M | $12.97M |
| Short-term debt | $20.40M | $19.67M | $14.12M | $8.77M | $3.60M | - | - | $0 | - | - | - | - |
| Total debt | $26.27M | $31.57M | $31.05M | $31.16M | $30.65M | $29.88M | $29.53M | $29.42M | $29.67M | $29.38M | $30.21M | $29.90M |
| Total liabilities | $50.95M | $58.74M | $46.15M | $52.40M | $49.05M | $54.82M | $48.96M | $57.18M | $49.77M | $44.97M | $38.93M | $43.15M |
| Shareholders' equity | $34.61M | $57.26M | $87.48M | $70.43M | $93.17M | $117.08M | $155.52M | $181.82M | $217.20M | $243.95M | $262.03M | $266.97M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$26.65M | -$18.07M | -$24.13M | -$19.10M | -$30.49M | -$31.83M | -$34.12M | -$27.21M | -$24.60M | -$16.55M | -$17.86M | -$8.31M |
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $9.0K | $79.0K | $0 | $0 | $5.0K | $11.0K | $14.0K |
| Free cash flow | -$26.65M | -$18.07M | -$24.13M | -$19.10M | -$30.49M | -$31.84M | -$34.20M | -$27.21M | -$24.60M | -$16.55M | -$17.87M | -$8.33M |
| Investing cash flow | $25.25M | $26.00M | -$13.81M | $26.25M | $40.51M | $38.48M | $28.69M | $29.66M | -$10.13M | $37.70M | -$9.20M | -$48.81M |
| Financing cash flow | -$4.96M | -$278.0K | $35.74M | $2.0K | $0 | $0 | -$36.0K | -$9.0K | -$42.0K | -$128.0K | $7.11M | $29.13M |
| Stock-based compensation | $2.71M | $2.52M | $2.40M | $2.42M | $2.46M | $2.50M | $2.47M | $2.34M | $2.34M | $2.47M | $2.48M | $1.63M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | - | - | 118.6% | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - | -443.8% | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | -371.4% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - | -446.2% | - |
| Current ratio | 1.89 | 2.47 | 4.55 | 4.07 | 6.02 | 5.97 | 8.02 | 6.46 | 10.43 | 17.37 | 30.20 | 19.01 |
| Debt to equity | 0.76 | 0.55 | 0.35 | 0.44 | 0.33 | 0.26 | 0.19 | 0.16 | 0.14 | 0.12 | 0.12 | 0.11 |
Source: XBRL data Acumen Pharmaceuticals Inc. files with the SEC, latest filing dated Oct 26, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ABOS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ABOS | - | - | -$103.96M | - | $17.6M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
ABOS FAQ
6 questionsIs ABOS profitable?
No. Acumen Pharmaceuticals Inc. reported a net loss of $103.96M for the twelve months ended Sep 30, 2026.How much cash and debt does ABOS have?
Acumen Pharmaceuticals Inc. reported $53.08M in cash and cash equivalents and $26.27M of debt on its most recent balance sheet in SEC filings.What is ABOS free cash flow?
Acumen Pharmaceuticals Inc. generated -$87.95M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$87.95M less capital expenditures.What is ABOS earnings per share?
Diluted earnings per share were -$1.53 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did ABOS last report financial results?
The latest statements here come from Acumen Pharmaceuticals Inc.'s 10-Q filed on Oct 26, 2026, covering the period ended Sep 30, 2026.Where does this ABOS financial data come from?
Quantisnow builds these statements from the structured XBRL data Acumen Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.